vida: extract claims from 2026-05-05-timmermanreport-dark-side-glp1-eating-disorders

- Source: inbox/queue/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific.md

@@ -45,3 +45,10 @@ Australian DAEN database shows exceptionally high ROR (17.66) for dulaglutide ea
 **Source:** NBC News 2024-08-15
 
 FDA adverse event analysis found 'greater risk of abuse among patients taking semaglutide' compared to other weight-loss drugs (not quantified). Psychologist Tom Hildebrandt reports increase in ED patients taking GLP-1s over 6-month observation window. Journal of Clinical Psychopharmacology published case of patient abusing medication, losing 50 lbs in 9 months. All evidence remains case-report or clinical observation level as of August 2024.
+
+
+## Supporting Evidence
+
+**Source:** ISPOR study via Timmerman Report, November 2025
+
+ISPOR study of 60,000+ GLP-1 users found 1.275% cumulative eating disorder incidence (mainly anorexia nervosa), with prior mental health conditions doubling risk. This confirms the pharmacovigilance signal is detectable in large-scale observational data and identifies behavioral substrate as primary risk stratifier.

domains/health/glp1-eating-disorder-risk-doubles-with-prior-mental-health-history.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: ISPOR study of 60,000+ GLP-1 users found those with prior mental health conditions had more than double the eating disorder incidence versus those without mental health history
+confidence: experimental
+source: ISPOR study via Timmerman Report, n=60,000+ GLP-1 users
+created: 2026-05-05
+title: GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population
+agent: vida
+sourced_from: health/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md
+scope: correlational
+sourcer: Luke Timmerman (Timmerman Report)
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+---
+
+# GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population
+
+The ISPOR study analyzed over 60,000 GLP-1 users and found cumulative eating disorder incidence of 1.275% across all users, with a critical stratification: GLP-1 users with prior mental health conditions had MORE THAN DOUBLE the eating disorder risk compared to GLP-1 users without mental health history. This is a within-GLP-1-users comparison, not a comparison to non-GLP-1 controls, meaning the study identifies a behavioral substrate that predicts differential risk among those prescribed the medication. The finding establishes prior mental health history as the primary risk stratifier for GLP-1-associated eating disorders, creating an identifiable high-risk population. However, the study lacks a non-GLP-1 control group, so it cannot establish whether GLP-1 elevates absolute eating disorder risk above baseline in weight-management-seeking populations. The eating disorders were mainly anorexia nervosa diagnoses.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -45,3 +45,10 @@ Collaborative of Eating Disorders Organizations calling for mandatory screening
 **Source:** PMC12694361 systematic review
 
 Review frames GLP-1RAs as 'at the intersection of medical innovation and psychological risk' requiring 'integrated psychological monitoring within multidisciplinary care.' This operationalizes the structural capacity requirement through specific screening infrastructure rather than individual clinician knowledge.
+
+
+## Extending Evidence
+
+**Source:** Timmerman Report regulatory analysis, November 2025
+
+Timmerman Report documents that semaglutide labels do not include warnings for restrictive eating disorder risk, and no safety database exists for monitoring GLP-1-induced eating disorders. The regulatory gap extends beyond screening protocols to include labeling and post-market surveillance infrastructure.

domains/health/glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: No standard protocol for eating disorder screening before GLP-1 prescribing exists, and semaglutide labels lack restrictive eating disorder warnings despite pharmacovigilance signals
+confidence: experimental
+source: Timmerman Report regulatory gap analysis, November 2025
+created: 2026-05-05
+title: GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
+agent: vida
+sourced_from: health/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md
+scope: structural
+sourcer: Luke Timmerman (Timmerman Report)
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+---
+
+# GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
+
+Despite evidence of elevated eating disorder risk in GLP-1 users with prior mental health conditions, the prescribing infrastructure lacks systematic screening protocols. Timmerman Report documents that: (1) no standard protocol for eating disorder screening before prescribing exists, (2) no safety database for monitoring GLP-1-induced eating disorders is operational, (3) no required clinical follow-up structure is in place, and (4) semaglutide labels do not include warnings for restrictive eating disorder risk. The article quotes an unspecified source stating 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.' This represents a structural gap where the clinical knowledge exists (prior mental health history doubles risk) but the operational infrastructure to act on it does not. The parallel to Z-code SDOH documentation is direct: screening would catch risk but there's no reimbursement or requirement to perform it.

inbox/archive/health/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md

@@ -7,10 +7,13 @@ date: 2025-11-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: medium
 tags: [glp-1, eating-disorders, ispor, pharmacovigilance, regulatory-gap, screening, anorexia]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content